Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640989 | 1.00 | SIGMAR1 (0.51) | SIGMAR1SLC18A3OPRM1OPRL1ALDH1A1 | |
| SCHEMBL13644021 | 0.87 | SIGMAR1 (0.51) | SIGMAR1SLC18A3OPRM1OPRL1ALDH1A1 | |
| SCHEMBL13640979 | 0.79 | HRH3 (0.47) | SIGMAR1SLC18A3OPRM1ALDH1A1CYP2D6 | |
| SCHEMBL13640762 | 0.76 | OPRM1 (0.53) | OPRM1OPRL1 | |
| SCHEMBL13640884 | 0.74 | MCHR2 (0.51) | SIGMAR1SLC18A3ALDH1A1 | |
| SCHEMBL13641051 | 0.74 | HDAC1 (0.44) | SIGMAR1SLC18A3 | |
| SCHEMBL13640906 | 0.74 | MCHR2 (0.51) | SIGMAR1SLC18A3ALDH1A1 | |
| SCHEMBL13640885 | 0.74 | MCHR2 (0.51) | SIGMAR1SLC18A3ALDH1A1 | |
| SCHEMBL14467579 | 0.74 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRL1ALDH1A1TP53 | |
| SCHEMBL13643889 | 0.74 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRL1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | SIGMAR1 253/4885SLC18A3 319/4885OPRM1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.